phenylpropanolamine has been researched along with Bladder, Overactive in 197 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 105 (53.30) | 29.6817 |
2010's | 91 (46.19) | 24.3611 |
2020's | 1 (0.51) | 2.80 |
Authors | Studies |
---|---|
Deo, A; Dhamala, JN; Pradhan, T; Yadav, SK | 1 |
Wein, AJ | 1 |
Kasyan, GR; Kupriyanov, YA; Pushkar, DY | 1 |
Devlin, N; Hakimi, Z; Herdman, M; Hoyle, C; Nazir, J; Odeyemi, IA; Pavesi, M | 1 |
Angulo, JC; Blauwet, MB; Cambronero, J; Dorrepaal, C; Herschorn, S; Khullar, V; Martin, NE; Nitti, VW; Siddiqui, E; van Kerrebroeck, P | 1 |
Mauseth, SA; Skurtveit, S; Spigset, O | 1 |
De Nunzio, C; Tubaro, A | 1 |
Creanga, D; Ginsberg, D; Kelleher, C; Martire, DL; Schneider, T; Swift, S; Van Kerrebroeck, P | 1 |
Abrams, P; Hart, WM; Munro, V; Nazir, J; Retsa, P | 1 |
Barkin, J; Chughtai, B; Elterman, DS; Kaplan, SA | 1 |
Li, Y; Liu, X; Shi, Y; Sui, C; Sun, F; Wu, Y; Zhou, Y | 1 |
Abrams, P; Andersson, KE; Chapple, CR; Deacon, S; Kuwayama, T; Masuda, T; Radziszewski, P; Small, M | 1 |
Kishi, M; Ogata, T; Shibata, C; Sugiyama, M; Takahashi, O; Tateno, F; Tsuyusaki, Y; Uchiyama, T; Yamamoto, T; Yamanishi, T; Yano, M | 1 |
de Groat, WC; Matsuta, Y; Roppolo, JR; Schwen, Z; Shen, B; Tai, C; Wang, J | 1 |
Lin, KL; Liu, CM; Long, CY; Shen, CJ; Wang, CL; Wu, CH | 1 |
Jiang, YH; Kuo, HC; Liu, HT | 1 |
Akino, H; Fujiuchi, Y; Fuse, H; Kitagawa, Y; Miyazawa, K; Namiki, M; Suzuki, K; Yokoyama, O | 1 |
Arumi, D; Lizarraga, I; Miranda, P; Rejas, J; Sánchez-Ballester, F | 1 |
Aguado-Jodar, A; Ibáñez-Nolla, J; Kvasz, M; Navarro-Artieda, R; Rejas, J; Ruiz-Torrejón, A; Sicras-Mainar, A | 1 |
He, JY; Shi, GW; Wang, YY; Zhang, YB | 1 |
Gotoh, M; Homma, Y; Igawa, Y; Ikeda, Y; Kakizaki, H; Marui, E; Nishizawa, O; Ohkawa, S; Seki, N; Takeda, M; Yamaguchi, O; Yokoyama, O; Yoshida, M | 1 |
Angulo, JC; Kvasz, M; Linden, K; Rejas, J; Snedecor, SJ; Valpas, A | 1 |
Herschorn, S; Kaplan, SA; Ntanios, F; Sun, F | 1 |
Costello, AJ; Cummings, SR; Jacobs, BP; Lipset, CH; Orri, M | 1 |
Dai, W; Fu, L; Li, Y; Liu, W; Liu, X; Sun, F; Teng, L; Wu, Y; Zhao, J | 1 |
Kosilov, KV; Kosilova, LV; Krasnykh, MA; Loparev, SA | 1 |
Blauwet, MB; Chapple, CR; Huang, M; Kaplan, SA; Khullar, V; Mitcheson, D; Siddiqui, E | 1 |
Bu, SY; Cao, CX; Duan, X; Peng, CD; Wang, KJ; Wu, T | 1 |
Chen, J; Guo, C; Liao, X; Tang, H; Wang, Y; Yu, T | 1 |
Athanasopoulos, A; Gibson, W; Goldman, H; Madersbacher, H; Newman, D; Spinks, J; Wagg, A; Wyndaele, JJ | 1 |
Brunocilla, E; Carini, M; De Nunzio, C; Gacci, M; Gravas, S; Novara, G; Oelke, M; Salvi, M; Schiavina, R; Sebastianelli, A; Serni, S; Tubaro, A | 1 |
Li, J; Li, P; Liu, B; Wang, Y; Wu, Y | 1 |
Eftekhar, T; Ghajarzadeh, M; Miri, E; Naeimi, M; Nikfallah, A; Teimoory, N | 1 |
Aballéa, S; Garnham, A; Hakimi, Z; Maman, K; Nazir, J; Odeyemi, IA; Thokagevistk, K; Toumi, M | 1 |
Ariogul, S; Cankurtaran, E; Cankurtaran, M; Ergen, A; Esin, E; Halil, M; Kuyumcu, ME; Ozcan, M; Ulger, Z; Yavuz, BB; Yeşil, Y | 1 |
Azimi Nekoo, E; Ghanbari, Z; Haghollahi, F; Hashemi, S; Jafarabadi, M; Nemati, M | 1 |
Chiang, CH; Chin, Hy; Lin, KC; Wang, CJ | 2 |
Bavendam, T; Carlsson, M; Chancellor, M; Guan, Z; Kaplan, SA; Roehrborn, CG | 1 |
Bolodeoku, J; Khullar, V; Mundy, A; Odeyemi, I; Speakman, M | 1 |
Porru, D | 2 |
Bavendam, T; Guan, Z; Jones, JS; Kaplan, SA; Roehrborn, CG; Wang, JT | 1 |
Wyndaele, JJ | 2 |
Rembratt, A | 1 |
Bolis, P; Cardozo, L; Salvatore, S; Serati, M; Uccella, S | 2 |
Artibani, W; Cavalleri, S; D'Elia, C; Ficarra, V; Galfano, A; Novara, G; Secco, S | 1 |
Bavendam, T; Carlsson, M; Guan, Z; Kaplan, SA; Kreder, K; Rovner, ES; Sussman, DO | 1 |
Guan, Z; Nitti, VW; Rackley, R; Rovner, ES; Wang, JT | 1 |
Brodsky, M; Chapple, CR; Jünemann, KP; Van Kerrebroeck, PE; Wang, JT | 1 |
Bachmann, G; Bavendam, T; Guan, Z; Jumadilova, Z; Morrow, JD; Rogers, R; Sun, F | 1 |
Azaripour, A; Hajebrahimi, S; Sadeghi-Bazargani, H | 1 |
Bavendam, T; Guan, Z; Kaplan, SA; Kraus, SR; Roehrborn, CG; Wang, JT | 1 |
MacDiarmid, S; Malhotra, BK; Sandage, BW | 1 |
Capo', JP; Chancellor, MB; Forero-Schwanhaeuser, S; Karram, M; Kobashi, K; Laramée, C; Nandy, I; Seifeldin, R; Siami, P; Snyder, JA; Whitmore, K; Zinner, N | 1 |
Burcher, E; Chandran, JJ; Christopoulos, A; Mansfield, KJ; Millard, RJ; Mitchelson, FJ; Vaux, KJ | 1 |
Brodsky, M; Castro-Diaz, D; Guan, Z; Heesakkers, J; Herschorn, S; Wang, JT | 1 |
Abrams, P; Brodsky, M; Chapple, C; Guan, Z; Herschorn, S; Sun, F | 1 |
Dmochowski, R | 1 |
Speakman, MJ | 1 |
Chang, YL; Ko, YJ; Lloyd, LK; Soong, YK; Tseng, LH; Wang, AC | 1 |
Bachmann, G; Morrow, JD; Omotosho, T; Rogers, RG; Sun, F | 1 |
Malhotra, B; Simon, HU | 1 |
Yoshinaga, Y | 1 |
Endeshaw, Y; Johnson, TM; Nagamia, Z; Ouslander, JG; Vaughan, CP | 1 |
Chancellor, MB; Kuo, HC; Liu, HT | 1 |
Brodsky, M; Coyne, KS; Kelleher, CJ; Kopp, Z; Van Kerrebroeck, PE; Wang, JT | 1 |
Al-Buheissi, S; Malone-Lee, JG | 1 |
Forero-Schwanhaeuser, S; Siami, P; Swift, SE | 1 |
Bavendam, T; Berriman, S; Burgio, KL; Guan, Z; Klutke, CG; Sun, F; Wyman, JF | 1 |
Axelsen, S; Kulseng-Hansen, S; Mattiasson, A; Milsom, I; Nilsson, CG; Wickstrøm, J | 1 |
Iannazzo, S; Pradelli, L | 1 |
Bavendam, T; Creanga, DL; Morrow, JD; Nitti, VW; Sand, PK | 1 |
Ulahannan, D; Wagg, A | 1 |
Bachmann, G; Bavendam, T; Guan, Z; Jumadilova, Z; Morrow, JD; Rogers, RG; Scarpero, H; Sun, F | 1 |
Feagins, BA; Jarnagin, BK; Leong, FC; Macdiarmid, SA; Peters, KM; Rosenblatt, PL; Rovner, ES; Shobeiri, SA; Siegel, SW; Tate, SB; Wooldridge, LS | 1 |
Carlsson, M; Glasser, DB; Griebling, TL; Kraus, SR; Richter, HE | 1 |
Altman, D; Falconer, C; Granath, F; Mattiasson, A | 1 |
Gauruder-Burmester, A; Popken, G | 1 |
Bolduc, S; Hamel, M; Lamontagne, P; Lebel, S; Moore, K | 1 |
Yang, SS | 1 |
Jorgensen, TM | 1 |
de Jong, TP | 1 |
Goode, P; Litman, HJ; Mueller, E; Norton, P; Zimmern, P | 1 |
Dolder, C; Olin, JL; Tzefos, M | 1 |
Burkart, M; Höfner, K; Jacob, G; Jonas, U | 2 |
Fukuhara, S; Hirai, T; Kiuchi, H; Kojimaan, Y; Miyagawa, Y; Nakayama, J; Okuyama, A; Takahashi, T; Takao, T; Tsujimura, A; Uchida, K; Ueda, T; Yamamoto, K | 1 |
Yokoyama, O | 1 |
Brodsky, M; Carlsson, M; Gong, J; Guan, Z; Herschorn, S; Morrow, JD; Swift, S | 1 |
Cardozo, L; Sidhu, M; Thorpe, A; Warner, J | 1 |
Mehnert, U; Sauermann, P; Schiffers, M; Schurch, B | 1 |
Chung, DE; Kaplan, SA; Staskin, DR; Te, AE | 1 |
Akyol, I; Alanbay, I; Atay, V; Ceyhan, ST; Muhcu, M; Mutlu Ercan, C; Sancaktar, M | 1 |
Faro, SH; Lebed, B; Lebovitch, S; Mohamed, FB; Moonat, S; Pontari, MA; Ruggieri, MR | 1 |
Andersson, AS; Bergqvist, A; Kowalski, J; Peeker, R; Samsioe, G | 1 |
Dmochowski, RR; Gomelsky, A | 1 |
Abrams, P; Brodsky, M; Chapple, CR; Guan, Z; Herschorn, S; Wang, JT | 1 |
Frenkl, TL; Green, S; Reiss, T; Rosenberg, E; Seltzer, O; Zhu, H | 1 |
Warner, JL | 1 |
Bavendam, T; Berriman, S; Burgio, K; Guan, Z; Klutke, C; Sun, F; Wyman, JF | 1 |
Carlsson, M; Foote, JE; Gong, J; Guan, Z; Kaplan, SA; Schneider, T | 1 |
Cossons, NH; Darekar, A; Marencak, J; Mills, IW | 1 |
Honda, M; Sakakibara, R; Uchiyama, T; Watanabe, M; Yamanishi, T; Yoshida, K | 1 |
Chang, TC; Ho, CH; Huang, KH; Lin, HH; Liu, SP; Yu, HJ | 1 |
Hui, JH; Lu, FD; Lv, JL; Tang, QN | 1 |
Chen, CJ; Deng, YJ; Ge, Z; Guo, YF; Lu, RG; Ma, G; Wang, LX; Zhu, HB | 1 |
Chapple, CR; Coyne, KS; Hsieh, R; Margolis, MK; Vats, V | 1 |
Chang, TC; Hsiao, SM; Lin, HH; Wu, WY | 1 |
Capo', JP; Forero-Schwanhaeuser, S; He, W; Lucente, V | 1 |
Chang, HC; Chiu, B; Chung, SD; Kuo, HC; Liao, CH | 1 |
Bungay, PJ; Callegari, E; Fenner, KS; Kay, GG; Kempshall, S; LaPerle, JL; Malhotra, B; Michel, MC; Webster, R | 1 |
Schröder, A; Thüroff, JW | 1 |
Chang, TC; Chen, CH; Hsiao, SM; Lin, HH; Wu, WY; Yu, HJ | 1 |
Gan, W; Jia, HT; Li, YF; Luo, MH; Xie, S; Zhang, SF | 1 |
Waters, H | 1 |
Brubaker, L; Fitzgerald, MP; Fordham, J; Kenton, K; Lowenstein, L; Mueller, ER; Rickey, L; Tulke, M | 1 |
Bailen, J; Beals, C; Burke, J; Frenkl, T; Railkar, R; Ruddy, M; Scott, BB; Shore, N; Sutherland, S | 1 |
Derpapas, A; Digesu, GA; Fernando, R; Hendricken, C; Khullar, V; Vijaya, G | 1 |
Blot, K; Falconer, C; Marschall-Kehrel, D; Michel, MC; Radziszewski, P | 1 |
Kaplan, SA | 1 |
Bercik, RS; Chen, HW; Thung, SF; Werner, EF | 1 |
Chen, Y; Fang, L; Li, C; Liu, C; Liu, J; Mu, L; Sun, L; Wang, Z; Xi, H | 1 |
Cody, JD; Ellis, G; Hay-Smith, EJ; Herbison, GP; Madhuvrata, P | 1 |
Han, P; Liu, L; Luo, D; Shen, H; Wei, Q | 1 |
Chen, YL; Feng, WJ; Zhang, XL | 1 |
Lin, Q; Lin, X; Shen, YZ | 1 |
Gillespie, JI; Guerard, M; Guilloteau, V; Korstanje, C; Lluel, P; Palea, S | 1 |
Arumí, D; Castro-Diaz, D; Lizarraga, I; Miranda, P; Rejas, J; Sanchez-Ballester, F | 1 |
Alessandri, F; Candiani, M; Ferrero, S; Leone Roberti Maggiore, U; Origoni, M; Remorgida, V; Salvatore, S; Venturini, PL | 1 |
Bavendam, T; Creanga, D; DuBeau, CE; Kraus, SR; Morrow, JD | 1 |
Berghmans, B; Moossdorff-Steinhauser, HF | 1 |
Dede, FS; Dede, H; Dolen, İ; Sivaslioglu, AA | 1 |
Kaufman, RP | 1 |
Amarenco, G; Angulo, JC; Boerrigter, P; Cambronero, J; Chapple, C; Drogendijk, T; Høye, K; Khullar, V; Milsom, I; Radziszewski, P; Rechberger, T; Wooning, M | 1 |
Chapple, CR; Cummings, J; Dorrepaal, C; Drogendijk, T; Kaplan, SA; Klecka, J; Martin, N; Mitcheson, D | 1 |
Cornu, JN; Novara, G | 1 |
Chen, HQ; Li, Y; Qi, L; Zeng, F; Zhang, XY | 1 |
Jiang, XZ; Xu, C; Xu, ZS; Zhang, NZ; Zhao, HF | 1 |
Dmochowski, RR | 1 |
Anderson, RU; Barada, JH; Goldberg, RP; Kell, S; MacDiarmid, S; Serels, S | 1 |
Bavendam, T; Carlsson, M; Elinoff, V; Eyland, N; Glasser, DB; Roberts, R | 2 |
Goepel, M | 1 |
Kanofsky, JA; Nitti, VW | 1 |
Bavendam, T; Coyne, KS; Jumadilova, Z; Matza, LS; Thompson, C | 1 |
Hegde, SS; Michel, MC | 1 |
Schaefer, W | 1 |
Beck, E; Burkart, M; Goepel, M; Michel, MC; Oelke, M | 1 |
Abrams, P; Dmochowski, R; Guan, Z; Marschall-Kehrel, D; Wang, JT | 1 |
Bavendam, T; Carlsson, M; Guan, Z; Kaplan, SA; Roehrborn, CG; Rovner, ES | 1 |
Girase, P; Jumadilova, Z; Ollendorf, DA; Varadharajan, S | 1 |
Babu, R | 1 |
Guan, Z; Khullar, V; Wang, JT; Wein, AJ | 1 |
Choo, MS; Heo, KO; Lee, KS; Park, JT; Song, C | 1 |
Hatanaka, T; Miyata, K; Noguchi, Y; Ohtake, A; Okutsu, H; Saitoh, C; Sasamata, M; Sato, S; Suzuki, M; Ukai, M; Yuyama, H | 1 |
Kageyama, A; Oki, T; Takagi, Y; Uchida, S; Yamada, S | 1 |
MacDiarmid, S; Rogers, A | 1 |
Alberca, R; Barrero, R; Campoy, P; Cayuela, A; Mir, P; Pena, JM | 1 |
Subramonian, K; Young, JG | 1 |
Amarshi, N; Bell, WA | 1 |
Chapple, C | 1 |
Carlsson, M; Guan, Z; Kraus, SR; Sussman, DO | 1 |
Bertozzi, R; Cipriani, S; Colli, E; Meschia, M; Montorsi, F; Olivieri, L; Parazzini, F | 1 |
Chancellor, MB; de Miguel, F | 1 |
Newman, DK; Page, SA; Rosenberg, MT; Tallman, CT | 1 |
Carlsson, M; Dmochowski, R; Guan, Z; Kreder, K; MacDiarmid, S | 1 |
Blaivas, JG; Guan, Z; Jones, M; Wang, JT; Weiss, JP | 1 |
Bolodeoku, J; Chapple, CR; Fianu-Jonsson, A; Indig, M; Khullar, V; Mistry, A; Rosa, J; Scarpa, RM; Wright, DM | 1 |
Bolge, SC; Chen, A; McDonnell, DD; Wan, GJ | 1 |
Christoph, F; Kempkensteffen, C; Miller, K; Moschkowitsch, A; Schostak, M; Schrader, M | 1 |
Brodsky, M; Chapple, C; Forst, HT; Haag-Molkenteller, C; Massow, U; Tubaro, A; Van Kerrebroeck, P; Wang, J | 1 |
Berglund, L; Brundin, L; Ehren, I; Farrelly, E; Hultling, C; Lafolie, P; Volz, D | 1 |
Bolodeoku, J; Cardozo, L; Robinson, D; Terpstra, G | 1 |
Bolis, P; Cromi, A; Ghezzi, F; Salvatore, S; Serati, M; Uccella, S | 1 |
Akino, H; Aoki, Y; Ito, H; Matsuta, Y; Miwa, Y; Nakai, M; Oyama, N; Tanase, K; Yokoyama, O; Yusup, A | 1 |
Roumeguère, T | 1 |
Kuo, HC | 1 |
Bolis, P; Cardozo, L; Cromi, A; Khullar, V; Salvatore, S; Serati, M; Uccella, S | 1 |
Olshansky, B; Serra, DB | 1 |
Davila, GW | 1 |
Hilas, O; Lam, S | 1 |
Bolis, P; Digesu, GA; Khullar, V; Salvatore, S; Serati, M; Triacca, P; Uccella, S | 1 |
Choo, MS; Doo, CK; Lee, KS | 1 |
Arai, Y; Chancellor, MB; Kaiho, Y; Kwon, DD; Nishiguchi, J; Snyder, PB; Yoshimura, N | 1 |
Hasuike, N; Maruyama, S; Suzuki, K; Yamada, S | 1 |
Andrews, CN; Bharucha, AE; Guan, Z; Seide, B; Zinsmeister, AR | 1 |
Bolis, P; Salvatore, S; Serati, M | 1 |
Marshall, T; Noe, L; Rasouliyan, L; Seifeldin, R; Zinner, N | 1 |
Ariely, R; D'Souza, AO; Doyle, J; Miller, LA; Smith, MJ | 1 |
Brodsky, M; Carlsson, M; Coyne, KS; Deng, DY; Elinoff, V; Glasser, DB; Gordon, DA; Jumadilova, Z | 1 |
Culley, EJ; Thomas, L | 1 |
Chancellor, MB; Chuang, YC; Thomas, CA; Tyagi, P; Tyagi, S; Yoshimura, N | 1 |
30 review(s) available for phenylpropanolamine and Bladder, Overactive
Article | Year |
---|---|
Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies.
Topics: Acetanilides; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Clinical Trials, Phase III as Topic; Cresols; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Muscarinic Antagonists; Phenylpropanolamine; Randomized Controlled Trials as Topic; Thiazoles; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urological Agents; Young Adult | 2013 |
Tolterodine for the treatment of urge urinary incontinence.
Topics: Benzhydryl Compounds; Cresols; Humans; Muscarinic Antagonists; Phenylpropanolamine; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence, Urge; Urological Agents | 2013 |
Cost effectiveness of fesoterodine and tolterodine for the treatment of overactive bladder with urge urinary incontinence in Spain and Finland.
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Cresols; Finland; Humans; Phenylpropanolamine; Spain; Tolterodine Tartrate; Urinary Bladder, Overactive; Urinary Incontinence, Urge | 2014 |
The role of mirabegron in overactive bladder: a systematic review and meta-analysis.
Topics: Acetanilides; Benzhydryl Compounds; Cresols; Humans; Muscarinic Antagonists; Odds Ratio; Phenylpropanolamine; Prospective Studies; Research Design; Software; Surveys and Questionnaires; Thiazoles; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urination; Urological Agents | 2014 |
Tolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review.
Topics: Adrenergic alpha-Antagonists; Benzhydryl Compounds; Constipation; Cresols; Delayed-Action Preparations; Drug Therapy, Combination; Humans; Lower Urinary Tract Symptoms; Male; Muscarinic Antagonists; Phenylpropanolamine; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents; Xerostomia | 2014 |
[Comparisons of therapeutic efficacy and safety of solifenacin versus tolterodine in patients with overactive bladder: a meta-analysis of outcomes].
Topics: Benzhydryl Compounds; Constipation; Cresols; Humans; Phenylpropanolamine; Quinuclidines; Safety; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence, Urge; Xerostomia | 2014 |
A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder.
Topics: Benzhydryl Compounds; Cresols; Humans; Mandelic Acids; Muscarinic Antagonists; Phenylpropanolamine; Randomized Controlled Trials as Topic; Tolterodine Tartrate; Urinary Bladder, Overactive | 2008 |
[Multinational clinical trial in Japan and Korea on detrusitol].
Topics: Benzhydryl Compounds; Cresols; Double-Blind Method; Female; Humans; International Cooperation; Japan; Korea; Male; Mandelic Acids; Multicenter Studies as Topic; Muscarinic Antagonists; Phenylpropanolamine; Randomized Controlled Trials as Topic; Tolterodine Tartrate; Urinary Bladder, Overactive | 2009 |
The safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderly.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Tolterodine Tartrate; Urinary Bladder, Overactive | 2009 |
Tolterodine extended release is well tolerated in older subjects.
Topics: Adult; Aged; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Randomized Controlled Trials as Topic; Retrospective Studies; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2009 |
Fesoterodine for the treatment of overactive bladder.
Topics: Animals; Benzhydryl Compounds; Cresols; Humans; Muscarinic Antagonists; Phenylpropanolamine; Quality of Life; Randomized Controlled Trials as Topic; Tolterodine Tartrate; Urinary Bladder, Overactive | 2009 |
New strategies for medical management of overactive bladder in children.
Topics: Benzhydryl Compounds; Benzilates; Botulinum Toxins; Child; Cresols; Humans; Mandelic Acids; Muscarinic Antagonists; Nortropanes; Phenylpropanolamine; Quinuclidines; Receptors, Muscarinic; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive; Urination | 2010 |
Which anticholinergic drug for overactive bladder symptoms in adults.
Topics: Adult; Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Humans; Mandelic Acids; Phenylpropanolamine; Quinuclidines; Randomized Controlled Trials as Topic; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive; Urinary Incontinence | 2012 |
Solifenacin for overactive bladder: a systematic review and meta-analysis.
Topics: Benzhydryl Compounds; Cresols; Dose-Response Relationship, Drug; Humans; Muscarinic Antagonists; Phenylpropanolamine; Quinuclidines; Randomized Controlled Trials as Topic; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2012 |
Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females.
Topics: Benzhydryl Compounds; Benzilates; Benzofurans; Chronic Disease; Cresols; Drug Combinations; Female; Humans; Imidazoles; Mandelic Acids; Muscarinic Antagonists; Nocturia; Phenylpropanolamine; Pyrrolidines; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive; Urinary Incontinence | 2012 |
Effects of percutaneous tibial nerve stimulation on adult patients with overactive bladder syndrome: a systematic review.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cholinergic Antagonists; Clinical Trials as Topic; Cresols; Evidence-Based Medicine; Female; Humans; Male; Middle Aged; Nocturnal Enuresis; Phenylpropanolamine; Tibial Nerve; Time Factors; Tolterodine Tartrate; Transcutaneous Electric Nerve Stimulation; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive; Urinary Incontinence, Urge; Urodynamics; Young Adult | 2013 |
[Safety of solifenacin and tolterodine in the treatment of overactive bladder: a meta-analysis].
Topics: Benzhydryl Compounds; Cresols; Humans; Muscarinic Antagonists; Phenylpropanolamine; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2012 |
The puzzle of overactive bladder: controversies, inconsistencies, and insights.
Topics: Animals; Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Female; Humans; Mandelic Acids; Muscarinic Antagonists; Muscle Contraction; Parasympatholytics; Patient Compliance; Phenylpropanolamine; Quality of Life; Tolterodine Tartrate; Urinary Bladder; Urinary Bladder, Overactive | 2006 |
Tolterodine for treatment of overactive bladder.
Topics: Benzhydryl Compounds; Clinical Trials as Topic; Cresols; Delayed-Action Preparations; Humans; Muscarinic Antagonists; Phenylpropanolamine; Tolterodine Tartrate; Urinary Bladder, Overactive | 2006 |
Treatment of the overactive bladder syndrome with muscarinic receptor antagonists: a matter of metabolites?
Topics: Benzhydryl Compounds; Benzilates; Benzofurans; Cresols; Humans; Mandelic Acids; Muscarinic Antagonists; Nortropanes; Parasympatholytics; Phenylpropanolamine; Pyrrolidines; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive | 2006 |
Male overactive bladder: the role of urodynamics and anticholinergics.
Topics: Adult; Aged; Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Cystoscopy; Follow-Up Studies; Humans; Male; Mandelic Acids; Middle Aged; Multicenter Studies as Topic; Phenylpropanolamine; Randomized Controlled Trials as Topic; Risk Assessment; Severity of Illness Index; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder Neck Obstruction; Urinary Bladder, Overactive; Urodynamics | 2007 |
Number of daytime micturitions and volume voided per micturition in the evaluation of efficacy of drugs for overactive bladder: findings from randomized clinical trials.
Topics: Benzhydryl Compounds; Cresols; Humans; Mandelic Acids; Muscarinic Antagonists; Phenylpropanolamine; Quinuclidines; Randomized Controlled Trials as Topic; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive; Urination | 2007 |
Treatment of overactive bladder: selective use of anticholinergic agents with low drug-drug interaction potential.
Topics: Benzhydryl Compounds; Benzilates; Cholinergic Antagonists; Cresols; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Mandelic Acids; Muscarinic Antagonists; Nortropanes; Phenylpropanolamine; Tolterodine Tartrate; Urinary Bladder, Overactive | 2007 |
Overactive bladder: recognition requires vigilance for symptoms.
Topics: Benzhydryl Compounds; Cost of Illness; Cresols; Female; Humans; Male; Mandelic Acids; Mass Screening; Muscarinic Antagonists; Phenylpropanolamine; Prevalence; Quality of Life; Tolterodine Tartrate; Urinary Bladder, Overactive | 2007 |
Update on drugs for overactive bladder syndrome.
Topics: Benzhydryl Compounds; Benzilates; Benzofurans; Cholinergic Antagonists; Cresols; Humans; Mandelic Acids; Muscarinic Antagonists; Phenylpropanolamine; Pyrrolidines; Quinuclidines; Randomized Controlled Trials as Topic; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive | 2007 |
Patient satisfaction with extended release tolterodine or oxybutynin in overactive bladder.
Topics: Aged; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Female; Humans; Male; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Patient Compliance; Patient Satisfaction; Phenylpropanolamine; Quality of Life; Tolterodine Tartrate; Urinary Bladder, Overactive | 2007 |
Transdermal oxybutynin in the treatment of overactive bladder.
Topics: Administration, Topical; Benzhydryl Compounds; Cresols; Humans; Mandelic Acids; Parasympatholytics; Patient Satisfaction; Phenylpropanolamine; Technology, Pharmaceutical; Tolterodine Tartrate; Urinary Bladder, Overactive | 2006 |
Pharmacologic management of overactive bladder.
Topics: Benzhydryl Compounds; Benzofurans; Cresols; Humans; Mandelic Acids; Muscarinic Antagonists; Nortropanes; Phenylpropanolamine; Pyrrolidines; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2007 |
Tolterodine for the treatment of overactive bladder.
Topics: Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Female; Humans; Male; Muscarinic Antagonists; Phenylpropanolamine; Quality of Life; Randomized Controlled Trials as Topic; Tolterodine Tartrate; Urinary Bladder, Overactive | 2008 |
Overactive bladder disease: the urge for better therapies.
Topics: Benzhydryl Compounds; Benzilates; Cresols; Delayed-Action Preparations; Female; Humans; Male; Muscarinic Antagonists; Nortropanes; Parasympatholytics; Patient Compliance; Phenylpropanolamine; Randomized Controlled Trials as Topic; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2008 |
82 trial(s) available for phenylpropanolamine and Bladder, Overactive
Article | Year |
---|---|
Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cresols; Double-Blind Method; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Prospective Studies; Tolterodine Tartrate; Urinary Bladder, Overactive; Young Adult | 2013 |
Phase II study on the efficacy and safety of the EP1 receptor antagonist ONO-8539 for nonneurogenic overactive bladder syndrome.
Topics: Adult; Aged; Benzhydryl Compounds; Cresols; Double-Blind Method; Female; Humans; Male; Middle Aged; Phenylpropanolamine; Receptors, Prostaglandin E, EP1 Subtype; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2014 |
[Cardura monotherapy versus combination therapy of cardura and tolterodine L-tartrate tablets for II° ? benign prostatic hyperplasia with overactive bladder].
Topics: Aged; Benzhydryl Compounds; Cresols; Doxazosin; Drug Therapy, Combination; Humans; Male; Middle Aged; Phenylpropanolamine; Prostatic Hyperplasia; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2013 |
Phase III, randomised, double-blind, placebo-controlled study of the β3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Asian People; Benzhydryl Compounds; Cresols; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Thiazoles; Tolterodine Tartrate; Urinary Bladder, Overactive | 2014 |
Do patient characteristics predict responsiveness to treatment of overactive bladder with antimuscarinic agents?
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cresols; Double-Blind Method; Female; Humans; Logistic Models; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Prognosis; Tolterodine Tartrate; Urinary Bladder, Overactive | 2014 |
Web-based trial to evaluate the efficacy and safety of tolterodine ER 4 mg in participants with overactive bladder: REMOTE trial.
Topics: Adult; Benzhydryl Compounds; Cell Phone; Cresols; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Internet; Middle Aged; Phenylpropanolamine; Research Design; Tolterodine Tartrate; Urinary Bladder, Overactive; Urological Agents | 2014 |
[Treatment of overactive bladder in older women increased doses of antimuscarinic drugs safe and effective alternative to existing methods].
Topics: Aged; Benzhydryl Compounds; Benzilates; Cresols; Dose-Response Relationship, Drug; Double-Blind Method; Drug Monitoring; Drug Synergism; Drug Therapy, Combination; Female; Humans; Mandelic Acids; Muscarinic Antagonists; Nortropanes; Phenylpropanolamine; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence, Urge; Urodynamics | 2014 |
Mirabegron 50 mg once-daily for the treatment of symptoms of overactive bladder: an overview of efficacy and tolerability over 12 weeks and 1 year.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Benzhydryl Compounds; Cresols; Double-Blind Method; Drug Administration Schedule; Female; Headache; Humans; Hypertension; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Thiazoles; Tolterodine Tartrate; Urinary Bladder, Overactive; Urinary Retention; Urinary Tract Infections; Urination; Xerostomia | 2014 |
Combination of sacral neuromodulation and tolterodine for treatment of idiopathic overactive bladder in women: a clinical trial.
Topics: Adult; Aged; Anxiety; Benzhydryl Compounds; Combined Modality Therapy; Cresols; Depression; Electric Stimulation Therapy; Female; Humans; Lumbosacral Plexus; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Psychiatric Status Rating Scales; Tolterodine Tartrate; Urinary Bladder, Overactive; Urine | 2014 |
Posterior tibial nerve stimulation for treating neurologic bladder in women: a randomized clinical trial.
Topics: Adult; Benzhydryl Compounds; Cresols; Electric Stimulation Therapy; Female; Humans; Middle Aged; Phenylpropanolamine; Rectum; Tibial Nerve; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Neurogenic; Urinary Bladder, Overactive | 2014 |
Cost effectiveness of mirabegron compared with tolterodine extended release for the treatment of adults with overactive bladder in the United Kingdom.
Topics: Acetanilides; Adult; Benzhydryl Compounds; Cost-Benefit Analysis; Cresols; Double-Blind Method; Humans; Phenylpropanolamine; Quality of Life; Thiazoles; Tolterodine Tartrate; United Kingdom; Urinary Bladder, Overactive; Urological Agents | 2015 |
Prominent complaint: a guide to medical therapy of overactive bladder syndrome in older women.
Topics: Aged; Benzhydryl Compounds; Cresols; Double-Blind Method; Female; Humans; Iran; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Quality of Life; Syndrome; Tolterodine Tartrate; Urinary Bladder, Overactive | 2015 |
Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Drug Therapy, Combination; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Prostatic Hyperplasia; Prostatism; Quality of Life; Sulfonamides; Surveys and Questionnaires; Tamsulosin; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2008 |
A cost-utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome.
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Cresols; Double-Blind Method; Humans; Markov Chains; Muscarinic Antagonists; Phenylpropanolamine; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive | 2008 |
Is there a synergistic effect of topical oestrogens when administered with antimuscarinics in the treatment of symptomatic detrusor overactivity?
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cresols; Drug Synergism; Drug Therapy, Combination; Estriol; Estrogens; Female; Humans; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Prospective Studies; Tolterodine Tartrate; Urinary Bladder, Overactive | 2009 |
Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms.
Topics: Adrenergic alpha-Antagonists; Adult; Analysis of Variance; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Drug Therapy, Combination; Humans; Male; Middle Aged; Muscarinic Antagonists; Patient Satisfaction; Phenylpropanolamine; Prostatic Hyperplasia; Sulfonamides; Surveys and Questionnaires; Tamsulosin; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence, Urge | 2008 |
Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder.
Topics: Aged; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Placebos; Time Factors; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urination | 2008 |
Comparison of fesoterodine and tolterodine in patients with overactive bladder.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Cresols; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Quality of Life; Surveys and Questionnaires; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urination Disorders; Urodynamics; Young Adult | 2008 |
Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cresols; Double-Blind Method; Emotions; Female; Follow-Up Studies; Humans; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Quality of Life; Sexuality; Surveys and Questionnaires; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Young Adult | 2008 |
Tolterodine immediate release improves sexual function in women with overactive bladder.
Topics: Adult; Arousal; Benzhydryl Compounds; Cresols; Female; Humans; Libido; Middle Aged; Muscarinic Antagonists; Orgasm; Phenylpropanolamine; Quality of Life; Sexual Behavior; Sexual Dysfunction, Physiological; Tolterodine Tartrate; Urinary Bladder, Overactive; Urinary Incontinence; Young Adult | 2008 |
Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
Topics: Adrenergic alpha-Antagonists; Aged; Benzhydryl Compounds; Cohort Studies; Cresols; Delayed-Action Preparations; Drug Therapy, Combination; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Predictive Value of Tests; Prostate-Specific Antigen; Prostatic Hyperplasia; Sulfonamides; Tamsulosin; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urination Disorders | 2008 |
Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
Topics: Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive | 2008 |
Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms*.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Canada; Cresols; Delayed-Action Preparations; Europe; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Surveys and Questionnaires; Time Factors; Tolterodine Tartrate; Turkey; Urinary Bladder; Urinary Bladder, Overactive | 2008 |
Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cresols; Double-Blind Method; Drug Therapy, Combination; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Prospective Studies; Prostatism; Tolterodine Tartrate; Urinary Bladder, Overactive | 2009 |
Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome.
Topics: Administration, Intravaginal; Aged; Benzhydryl Compounds; Cresols; Drug Therapy, Combination; Estrogens; Estrogens, Conjugated (USP); Female; Humans; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Postmenopause; Prospective Studies; Quality of Life; Surveys and Questionnaires; Syndrome; Time Factors; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics; Vaginal Creams, Foams, and Jellies | 2009 |
Continued symptom improvement in sexually active women with overactive bladder and urgency urinary incontinence treated with tolterodine ER for 6 months.
Topics: Adult; Anxiety; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Depression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Health Surveys; Humans; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Quality of Life; Sexual Behavior; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence, Urge | 2009 |
The pharmacokinetic profile of fesoterodine: similarities and differences to tolterodine.
Topics: Administration, Oral; Adolescent; Adult; Benzhydryl Compounds; Chromatography, Liquid; Cresols; Cross-Over Studies; Gas Chromatography-Mass Spectrometry; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Reference Values; Tolterodine Tartrate; Urinary Bladder, Overactive; Young Adult | 2009 |
Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study.
Topics: Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Quality of Life; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence, Urge; Urodynamics | 2009 |
Diary and patient-reported outcomes in patients with severe overactive bladder switching from tolterodine extended release 4 mg/day to solifenacin treatment: An open-label, flexible-dosing, multicentre study.
Topics: Aged; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Quality of Life; Quinuclidines; Severity of Illness Index; Solifenacin Succinate; Surveys and Questionnaires; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2009 |
Efficacy and tolerability of fesoterodine in women with overactive bladder.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Constipation; Cresols; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2009 |
Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Middle Aged; Muscarinic Antagonists; Patient Satisfaction; Phenylpropanolamine; Placebos; Sexual Behavior; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence, Urge; Young Adult | 2009 |
Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Electric Stimulation Therapy; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Tibial Nerve; Tolterodine Tartrate; Urinary Bladder, Overactive; Young Adult | 2009 |
[Follow-up at 24 months after treatment of overactive bladder with 0.2 % sodium chondroitin sulfate].
Topics: Administration, Intravesical; Administration, Oral; Adult; Aged; Benzhydryl Compounds; Cholinergic Antagonists; Chondroitin Sulfates; Combined Modality Therapy; Cresols; Female; Follow-Up Studies; Humans; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Prospective Studies; Quality of Life; Tolterodine Tartrate; Urinary Bladder, Overactive; Urodynamics | 2009 |
Double anticholinergic therapy for refractory overactive bladder.
Topics: Adolescent; Algorithms; Benzhydryl Compounds; Child; Cresols; Drug Therapy, Combination; Female; Humans; Male; Mandelic Acids; Muscarinic Antagonists; Phenylpropanolamine; Prospective Studies; Tolterodine Tartrate; Urinary Bladder, Overactive | 2009 |
Effect of fluid management on fluid intake and urge incontinence in a trial for overactive bladder in women.
Topics: Behavior Therapy; Benzhydryl Compounds; Combined Modality Therapy; Cresols; Female; Humans; Middle Aged; Muscarinic Antagonists; Patient Satisfaction; Phenylpropanolamine; Prospective Studies; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence, Urge; Urodynamics | 2010 |
Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Patient Satisfaction; Phenylpropanolamine; Quality of Life; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence, Urge; Young Adult | 2010 |
The effect of tolterodine 4 and 8 mg on the heart rate variability in healthy subjects.
Topics: Administration, Oral; Adult; Benzhydryl Compounds; Cresols; Dose-Response Relationship, Drug; Electrocardiography; Female; Heart Rate; Humans; Muscarinic Antagonists; Phenylpropanolamine; Supine Position; Tolterodine Tartrate; Urinary Bladder, Overactive | 2010 |
The outcome of adding peripheral neuromodulation (Stoller afferent neuro-stimulation) to anti-muscarinic therapy in women with severe overactive bladder.
Topics: Adult; Benzhydryl Compounds; Combined Modality Therapy; Cresols; Electric Stimulation Therapy; Female; Humans; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Prospective Studies; Quality of Life; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2010 |
Central nervous system findings on functional magnetic resonance imaging in patients before and after treatment with anticholinergic medication.
Topics: Benzhydryl Compounds; Brain; Cresols; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Placebos; Surveys and Questionnaires; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2010 |
Efficacy and safety of tolterodine extended-release in men with overactive bladder symptoms treated with an α-blocker: effect of baseline prostate-specific antigen concentration.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Drug Therapy, Combination; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Prostate-Specific Antigen; Prostatic Hyperplasia; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2010 |
A multicenter, double-blind, randomized, placebo controlled trial of a neurokinin-1 receptor antagonist for overactive bladder.
Topics: Benzhydryl Compounds; Cresols; Double-Blind Method; Female; Humans; Isoindoles; Male; Middle Aged; Muscarinic Antagonists; Neurokinin-1 Receptor Antagonists; Phenylpropanolamine; Tolterodine Tartrate; Urinary Bladder, Overactive | 2010 |
Effects of combined behavioral intervention and tolterodine on patient-reported outcomes.
Topics: Adult; Aged; Aged, 80 and over; Behavior Therapy; Benzhydryl Compounds; Combined Modality Therapy; Cresols; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Patient Satisfaction; Phenylpropanolamine; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Young Adult | 2010 |
Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Quality of Life; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence, Urge; Young Adult | 2011 |
Investigation of the clinical efficacy and safety of pregabalin alone or combined with tolterodine in female subjects with idiopathic overactive bladder.
Topics: Adult; Aged; Analgesics; Benzhydryl Compounds; Cresols; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; gamma-Aminobutyric Acid; Humans; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Pregabalin; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urination | 2011 |
Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cresols; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Prospective Studies; Quinuclidines; Solifenacin Succinate; Taiwan; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urination | 2010 |
Efficacy of tolterodine for medical treatment of intramural ureteral stone with vesical irritability.
Topics: Adult; Benzhydryl Compounds; Cresols; Female; Humans; Male; Muscarinic Antagonists; Pain; Pain Measurement; Phenylpropanolamine; Retrospective Studies; Tolterodine Tartrate; Treatment Outcome; Ureteral Calculi; Urinary Bladder, Overactive; Watchful Waiting | 2011 |
[Comparisons of efficacy and safety of tolterodine and oxybutynin in children with idiopathic overactive bladder].
Topics: Adolescent; Benzhydryl Compounds; Child; Child, Preschool; Cresols; Female; Humans; Male; Mandelic Acids; Muscarinic Antagonists; Phenylpropanolamine; Tolterodine Tartrate; Urinary Bladder, Overactive | 2011 |
Changes in urodynamic parameters after tolterodine treatment for female overactive bladder syndrome with or without voiding dysfunction.
Topics: Adult; Aged; Benzhydryl Compounds; Cresols; Female; Humans; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urination Disorders; Urodynamics | 2011 |
The efficacy of additive tolterodine extended release for 1-year in older men with storage symptoms and clinical benign proastatic hyperplasia.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Humans; International Cooperation; Male; Muscarinic Antagonists; Phenylpropanolamine; Prostatic Hyperplasia; Quality of Life; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Retention | 2011 |
Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome.
Topics: Adult; Aged; Benzhydryl Compounds; Cresols; Female; Humans; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive; Urodynamics | 2011 |
[Tolterodine tartrate combined with alpha-receptor blocker for benign prostatic hyperplasia with detrusor overactivity].
Topics: Adrenergic alpha-Antagonists; Aged; Benzhydryl Compounds; Cresols; Humans; Male; Muscarinic Antagonists; Phenylpropanolamine; Prostatic Hyperplasia; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2011 |
Evaluation of an experimental urodynamic platform to identify treatment effects: a randomized, placebo-controlled, crossover study in patients with overactive bladder.
Topics: Adult; Aged; Benzhydryl Compounds; Compliance; Cresols; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Prospective Studies; Reproducibility of Results; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive; Urination; Urodynamics | 2012 |
Antimuscarinic effects on current perception threshold: a prospective placebo control study.
Topics: Adult; Aged; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Double-Blind Method; Electric Stimulation; Female; Humans; Middle Aged; Muscarinic Antagonists; Nerve Fibers, Unmyelinated; Neurons, Afferent; Perception; Phenylpropanolamine; Prospective Studies; Tolterodine Tartrate; Treatment Outcome; Urethra; Urinary Bladder; Urinary Bladder, Overactive | 2012 |
Unexpected frequent hepatotoxicity of a prescription drug, flupirtine, marketed for about 30 years.
Topics: Aged; Aminopyridines; Analgesics; Benzhydryl Compounds; Chemical and Drug Induced Liver Injury; Cresols; Double-Blind Method; Female; Humans; Liver; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Syndrome; Tolterodine Tartrate; Urinary Bladder, Overactive | 2012 |
[Parkinson's disease combined with overactive bladder syndrome treated with acupuncture and medication].
Topics: Adult; Aged; Benzhydryl Compounds; Combined Modality Therapy; Cresols; Electroacupuncture; Female; Humans; Male; Middle Aged; Parkinson Disease; Phenylpropanolamine; Tolterodine Tartrate; Urinary Bladder, Overactive | 2012 |
[Overactive bladder after transurethral resection of prostate treated with electroacupuncture therapy and tolterodine].
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Combined Modality Therapy; Cresols; Electroacupuncture; Humans; Male; Middle Aged; Phenylpropanolamine; Postoperative Complications; Prostate; Tolterodine Tartrate; Transurethral Resection of Prostate; Urinary Bladder, Overactive | 2012 |
What is the success of drug treatment in urge urinary incontinence? What should be measured?
Topics: Adult; Benzhydryl Compounds; Benzilates; Cresols; Female; Humans; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Nortropanes; Phenylpropanolamine; Quality of Life; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence, Urge; Urodynamics | 2013 |
Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Australia; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Double-Blind Method; Europe; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Quality of Life; Single-Blind Method; Surveys and Questionnaires; Thiazoles; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence, Urge; Urination | 2013 |
Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Benzhydryl Compounds; Constipation; Cresols; Delayed-Action Preparations; Double-Blind Method; Female; Headache; Humans; Hypertension; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Single-Blind Method; Thiazoles; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence, Urge; Urinary Retention; Xerostomia | 2013 |
Comparative study of pelvic floor biofeedback training and tolterodine for treatment of detrusor after-contraction in posturination dribbling in children.
Topics: Adolescent; Benzhydryl Compounds; Biofeedback, Psychology; Child; Cresols; Female; Humans; Male; Muscarinic Antagonists; Muscle Contraction; Muscle, Smooth; Pelvic Floor; Phenylpropanolamine; Tolterodine Tartrate; Urinary Bladder; Urinary Bladder, Overactive; Urinary Incontinence; Urodynamics | 2012 |
Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder.
Topics: Adult; Aged; Benzhydryl Compounds; Cresols; Demography; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Patient Dropouts; Patient Participation; Phenylpropanolamine; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence, Urge | 2006 |
Symptom-specific efficacy of tolterodine extended release in patients with overactive bladder: the IMPACT trial.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Tolterodine Tartrate; Urinary Bladder, Overactive | 2006 |
Tolterodine extended release improves patient-reported outcomes in overactive bladder: results from the IMPACT trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Patient Satisfaction; Phenylpropanolamine; Quality of Life; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence | 2006 |
The responsiveness of the OAB-q among OAB patient subgroups.
Topics: Adaptation, Psychological; Aged; Benzhydryl Compounds; Cresols; Female; Humans; Male; Medical Records; Middle Aged; Muscarinic Agonists; Phenylpropanolamine; Sex Characteristics; Surveys and Questionnaires; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urination | 2007 |
Relationships among symptoms, bother, and treatment satisfaction in overactive bladder patients.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cluster Analysis; Cresols; Delayed-Action Preparations; Factor Analysis, Statistical; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Nocturia; Patient Satisfaction; Phenylpropanolamine; Principal Component Analysis; Statistics, Nonparametric; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence | 2007 |
Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder.
Topics: Benzhydryl Compounds; Cresols; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Single-Blind Method; Tolterodine Tartrate; Urinary Bladder, Overactive | 2007 |
Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Prostatic Hyperplasia; Sulfonamides; Tamsulosin; Tolterodine Tartrate; Urinary Bladder, Overactive; Urinary Incontinence, Urge | 2006 |
Effectiveness of tolterodine in nonneurogenic voiding dysfunction.
Topics: Benzhydryl Compounds; Child; Cresols; Delayed-Action Preparations; Enuresis; Female; Humans; Male; Muscarinic Antagonists; Phenylpropanolamine; Tolterodine Tartrate; Urinary Bladder, Overactive; Urinary Incontinence, Urge | 2006 |
Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cresols; Double-Blind Method; Female; Humans; Male; Medical Records; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Severity of Illness Index; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence | 2007 |
Effects of bladder training and/or tolterodine in female patients with overactive bladder syndrome: a prospective, randomized study.
Topics: Behavior Therapy; Benzhydryl Compounds; Combined Modality Therapy; Cresols; Female; Humans; Middle Aged; Muscarinic Antagonists; Outcome Assessment, Health Care; Phenylpropanolamine; Toilet Training; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2006 |
Onset of efficacy of tolterodine extended release in patients with overactive bladder.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Time Factors; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2007 |
The clinical efficacy of tolterodine extended-release is maintained for 24 h in patients with overactive bladder.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Male; Medical Records; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urodynamics | 2007 |
Age related pathogenesis of nocturia in patients with overactive bladder.
Topics: Age Factors; Aged; Benzhydryl Compounds; Cresols; Double-Blind Method; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Nocturia; Phenylpropanolamine; Polyuria; Retrospective Studies; Sex Factors; Tolterodine Tartrate; Urinary Bladder, Overactive; Urodynamics | 2007 |
Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg.
Topics: Aged; Benzhydryl Compounds; Cresols; Double-Blind Method; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Quinuclidines; Safety; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence, Stress; Urination | 2007 |
Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder.
Topics: Adult; Aged; Benzhydryl Compounds; Cresols; Double-Blind Method; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Patient Selection; Phenylpropanolamine; Safety; Tolterodine Tartrate; Urinary Bladder, Overactive; Urinary Incontinence; Urination | 2007 |
Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study.
Topics: Administration, Oral; Benzhydryl Compounds; Botulinum Toxins, Type A; Cresols; Double-Blind Method; Female; Humans; Male; Muscarinic Antagonists; Phenylpropanolamine; Quality of Life; Tolterodine Tartrate; Urinary Bladder, Overactive | 2007 |
A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Quality of Life; Single-Blind Method; Sulfonamides; Tamsulosin; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics | 2007 |
Safety and efficacy of tolterodine extended release in men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia.
Topics: Aged; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Prostatic Hyperplasia; Quality of Life; Regression Analysis; Severity of Illness Index; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence, Urge; Urodynamics | 2007 |
Satisfaction with tolterodine: assessing symptom-specific patient-reported goal achievement in the treatment of overactive bladder in female patients (STARGATE study).
Topics: Adult; Aged; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Female; Humans; Middle Aged; Muscarinic Antagonists; Patient Satisfaction; Phenylpropanolamine; Prospective Studies; Severity of Illness Index; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2008 |
Effect of tolterodine on gastrointestinal transit and bowel habits in healthy subjects.
Topics: Adult; Benzhydryl Compounds; Constipation; Cresols; Defecation; Double-Blind Method; Female; Gastrointestinal Motility; Gastrointestinal Transit; Humans; Male; Middle Aged; Phenylpropanolamine; Tolterodine Tartrate; Urinary Bladder, Overactive | 2008 |
Impact of solifenacin on resource utilization, work productivity and health utility in overactive bladder patients switching from tolterodine ER.
Topics: Activities of Daily Living; Aged; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Female; Health Services; Humans; Male; Middle Aged; Muscarinic Antagonists; Outcome Assessment, Health Care; Patient Acceptance of Health Care; Phenylpropanolamine; Quality of Life; Quinuclidines; Solifenacin Succinate; Surveys and Questionnaires; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive | 2008 |
Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine.
Topics: Benzhydryl Compounds; Cresols; Female; Health Status; Humans; Male; Middle Aged; Muscarinic Antagonists; Patient Satisfaction; Phenylpropanolamine; Quality of Life; Surveys and Questionnaires; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2008 |
85 other study(ies) available for phenylpropanolamine and Bladder, Overactive
Article | Year |
---|---|
Patient Perception of Bladder Condition after Treatment with Solifenacin and Tolterodine in Overactive Bladder Patients.
Topics: Benzhydryl Compounds; Cresols; Cross-Sectional Studies; Humans; Nepal; Perception; Phenylpropanolamine; Solifenacin Succinate; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder; Urinary Bladder Diseases; Urinary Bladder, Overactive | 2023 |
Re: Tolterodine ER Reduced Increased Bladder Wall Thickness in Women with Overactive Bladder. A Randomized, Placebo-Controlled, Double-Blind, Parallel Group Study.
Topics: Cresols; Double-Blind Method; Female; Humans; Phenylpropanolamine; Tolterodine Tartrate; Urinary Bladder, Overactive | 2019 |
[A role of fesoterodine in treatment of overactive bladder].
Topics: Benzhydryl Compounds; Cresols; Humans; Muscarinic Antagonists; Phenylpropanolamine; Quality of Life; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2018 |
Understanding the effects on HR-QoL of treatment for overactive bladder: a detailed analysis of EQ-5D clinical trial data for mirabegron.
Topics: Acetanilides; Analysis of Variance; Benzhydryl Compounds; Clinical Trials, Phase III as Topic; Cresols; Data Interpretation, Statistical; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Psychometrics; Quality-Adjusted Life Years; Sickness Impact Profile; Thiazoles; Tolterodine Tartrate; Urinary Bladder, Overactive | 2013 |
Adherence, persistence and switch rates for anticholinergic drugs used for overactive bladder in women: data from the Norwegian Prescription Database.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Benzofurans; Cholinergic Antagonists; Cresols; Databases, Pharmaceutical; Drug Substitution; Female; Follow-Up Studies; Humans; Medication Adherence; Middle Aged; Norway; Phenylpropanolamine; Pyrrolidines; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive; Young Adult | 2013 |
Flexible dose fesoterodine in the treatment of overactive bladder (OAB).
Topics: Benzhydryl Compounds; Cresols; Female; Humans; Male; Muscarinic Antagonists; Phenylpropanolamine; Tolterodine Tartrate; Urinary Bladder, Overactive | 2013 |
Cost-effectiveness analysis of solifenacin versus oxybutynin immediate-release in the treatment of patients with overactive bladder in the United Kingdom.
Topics: Benzhydryl Compounds; Cohort Studies; Cost-Benefit Analysis; Cresols; Humans; Incontinence Pads; Mandelic Acids; Markov Chains; Medication Adherence; Models, Economic; Muscarinic Antagonists; Patient Dropouts; Phenylpropanolamine; Quality-Adjusted Life Years; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; United Kingdom; Urinary Bladder, Overactive; Urinary Incontinence | 2013 |
Preparation, characterization and pharmacological evaluation of tolterodine hydrogels for the treatment of overactive bladder.
Topics: Acrylic Resins; Administration, Cutaneous; Animals; Benzhydryl Compounds; Biological Availability; Biotransformation; Chemistry, Pharmaceutical; Cresols; Drug Carriers; Hydrogels; Injections, Intravenous; Male; Mice; Models, Biological; Muscarinic Antagonists; Muscle Contraction; Permeability; Phenylpropanolamine; Pyrrolidinones; Rabbits; Rats; Skin; Skin Absorption; Skin Irritancy Tests; Technology, Pharmaceutical; Tolterodine Tartrate; Urinary Bladder; Urinary Bladder, Overactive; Urological Agents | 2013 |
Tolterodine activates the prefrontal cortex during bladder filling in OAB patients: a real-time NIRS-urodynamics study.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Cresols; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Prefrontal Cortex; Spectroscopy, Near-Infrared; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics; Urological Agents | 2014 |
Combination of foot stimulation and tolterodine treatment eliminates bladder overactivity in cats.
Topics: Animals; Benzhydryl Compounds; Cats; Combined Modality Therapy; Cresols; Female; Foot; Male; Muscarinic Antagonists; Phenylpropanolamine; Tolterodine Tartrate; Transcutaneous Electric Nerve Stimulation; Urinary Bladder, Overactive | 2014 |
Clinical and urodynamic effects of tolterodine in women with an overactive bladder.
Topics: Adult; Aged; Benzhydryl Compounds; Cresols; Female; Humans; Menopause; Middle Aged; Nocturia; Parity; Phenylpropanolamine; Pregnancy; Retrospective Studies; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence, Urge; Urodynamics; Urological Agents | 2013 |
Increased serum adipokines implicate chronic inflammation in the pathogenesis of overactive bladder syndrome refractory to antimuscarinic therapy.
Topics: Adipokines; Adult; Aged; Benzhydryl Compounds; C-Reactive Protein; Case-Control Studies; Cresols; Drug Resistance; Female; Humans; Inflammation; Male; Middle Aged; Muscarinic Antagonists; Nerve Growth Factor; Phenylpropanolamine; Prospective Studies; Tolterodine Tartrate; Urinary Bladder, Overactive | 2013 |
Factors influencing patient satisfaction with antimuscarinic treatment of overactive bladder syndrome: results of a real-life clinical study.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Benzilates; Cresols; Cross-Sectional Studies; Female; Humans; Imidazoles; Japan; Male; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Patient Satisfaction; Phenylpropanolamine; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2014 |
Therapeutic benefit in patients switching tolterodine to other novel antimuscarinic agents.
Topics: Activities of Daily Living; Adult; Aged; Benzhydryl Compounds; Comorbidity; Cresols; Cross-Sectional Studies; Drug Substitution; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Muscarinic Antagonists; Observational Studies as Topic; Patient Preference; Patient Satisfaction; Personal Satisfaction; Phenylpropanolamine; Physicians; Propensity Score; Quinuclidines; Retrospective Studies; Sample Size; Solifenacin Succinate; Tetrahydroisoquinolines; Therapeutic Equivalency; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents; Young Adult | 2014 |
Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain.
Topics: Aged; Benzhydryl Compounds; Cholinergic Agents; Cost-Benefit Analysis; Cresols; Female; Health Care Costs; Humans; Male; Phenylpropanolamine; Prevalence; Primary Health Care; Quinuclidines; Retrospective Studies; Solifenacin Succinate; Spain; Syndrome; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2013 |
Design of transparent film-forming hydrogels of tolterodine and their effects on stratum corneum.
Topics: Administration, Cutaneous; Animals; Benzhydryl Compounds; Cresols; Drug Carriers; Drug Compounding; Drug Design; Drug Liberation; Female; Hydrogels; Mice, Inbred Strains; Muscarinic Antagonists; Phase Transition; Phenylpropanolamine; Rats, Sprague-Dawley; Skin; Skin Absorption; Spectroscopy, Fourier Transform Infrared; Surface Properties; Tissue Distribution; Tolterodine Tartrate; Urinary Bladder, Overactive | 2014 |
Are we shortchanging frail older people when it comes to the pharmacological treatment of urgency urinary incontinence?
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Frail Elderly; Humans; Muscarinic Antagonists; Phenylpropanolamine; Urinary Bladder, Overactive; Urinary Incontinence | 2014 |
Influence of antimuscarinic therapy on cognitive functions and quality of life in geriatric patients treated for overactive bladder.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Benzhydryl Compounds; Benzilates; Benzofurans; Cognition Disorders; Cresols; Depression; Female; Follow-Up Studies; Geriatric Assessment; Humans; Male; Mandelic Acids; Muscarinic Antagonists; Nortropanes; Phenylpropanolamine; Pyrrolidines; Quality of Life; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2015 |
Single uroflow study as a tool in predicting the possibility of abnormal voiding symptoms after the administration of antimuscarinic agents in treating overactive bladder syndrome.
Topics: Adult; Aged; Benzhydryl Compounds; Cresols; Female; Humans; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Retrospective Studies; Syndrome; Tolterodine Tartrate; Urinary Bladder, Overactive; Urination Disorders; Urodynamics; Young Adult | 2015 |
Editorial comment on: Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size.
Topics: Adrenergic alpha-Antagonists; Aged; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Humans; Male; Middle Aged; Muscarinic Agonists; Organ Size; Phenylpropanolamine; Prostate; Randomized Controlled Trials as Topic; Sulfonamides; Tamsulosin; Tolterodine Tartrate; Urinary Bladder, Overactive; Urinary Tract; Urination | 2009 |
Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size.
Topics: Adrenergic alpha-Antagonists; Adult; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Diuresis; Drug Therapy, Combination; Humans; Male; Middle Aged; Multicenter Studies as Topic; Muscarinic Agonists; Organ Size; Phenylpropanolamine; Prostate; Randomized Controlled Trials as Topic; Sulfonamides; Tamsulosin; Tolterodine Tartrate; Urinary Bladder, Overactive; Urinary Retention | 2009 |
Editorial comment on: Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size.
Topics: Adrenergic alpha-Antagonists; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Drug Therapy, Combination; Humans; Male; Muscarinic Agonists; Organ Size; Phenylpropanolamine; Prostate; Safety; Sulfonamides; Tamsulosin; Tolterodine Tartrate; Urinary Bladder Neck Obstruction; Urinary Bladder, Overactive; Urologic Diseases | 2009 |
Editorial comment on: Is there a synergistic effect of topical oestrogens when administered with antimuscarinics in the treatment of symptomatic detrusor overactivity?
Topics: Administration, Topical; Benzhydryl Compounds; Cresols; Drug Synergism; Drug Therapy, Combination; Estrogens; Female; Humans; Muscarinic Antagonists; Phenylpropanolamine; Tolterodine Tartrate; Urinary Bladder, Overactive | 2009 |
Editorial comment on: Is there a synergistic effect of topical oestrogens when administered with antimuscarinics in the treatment of symptomatic detrusor overactivity?
Topics: Administration, Topical; Benzhydryl Compounds; Cresols; Drug Synergism; Drug Therapy, Combination; Estrogens; Female; Humans; Muscarinic Antagonists; Phenylpropanolamine; Tolterodine Tartrate; Urinary Bladder, Overactive | 2009 |
The effects of reformulation: improved therapeutic index.
Topics: Benzhydryl Compounds; Benzilates; Chemistry, Pharmaceutical; Cresols; Humans; Mandelic Acids; Muscarinic Antagonists; Nortropanes; Phenylpropanolamine; Tolterodine Tartrate; Urinary Bladder, Overactive | 2008 |
Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa.
Topics: Aged; Benzhydryl Compounds; Benzofurans; Cresols; Cystectomy; Female; Humans; Male; Middle Aged; Mucous Membrane; Muscarinic Antagonists; Phenylpropanolamine; Prostatectomy; Pyrrolidines; Quinuclidines; Quinuclidinyl Benzilate; Radioligand Assay; Receptors, Muscarinic; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder; Urinary Bladder, Overactive | 2009 |
Editorial comment on: Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
Topics: Adrenergic alpha-Antagonists; Benzhydryl Compounds; Cresols; Drug Therapy, Combination; Humans; Male; Muscarinic Antagonists; Phenylpropanolamine; Prostatism; Tolterodine Tartrate; Urinary Bladder, Overactive | 2009 |
Editorial comment on: Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
Topics: Adrenergic alpha-Antagonists; Benzhydryl Compounds; Cresols; Drug Therapy, Combination; Humans; Male; Muscarinic Antagonists; Phenylpropanolamine; Prostatism; Tolterodine Tartrate; Urinary Bladder, Overactive | 2009 |
A multicomponent behavioural and drug intervention for nocturia in elderly men: rationale and pilot results.
Topics: Acetamides; Adrenergic alpha-Antagonists; Aged; Behavior Therapy; Benzhydryl Compounds; Combined Modality Therapy; Cresols; Epidemiologic Methods; Humans; Hypnotics and Sedatives; Male; Middle Aged; Muscarinic Antagonists; Nocturia; Phenylpropanolamine; Prazosin; Prostatic Hyperplasia; Pyrimidines; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2009 |
Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Biomarkers; Case-Control Studies; Cresols; Enzyme-Linked Immunosorbent Assay; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Nerve Growth Factor; Phenylpropanolamine; Prognosis; Severity of Illness Index; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics | 2009 |
Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Benzhydryl Compounds; Cresols; Female; Humans; Male; Medical Records; Middle Aged; Muscarinic Antagonists; Patient Satisfaction; Phenylpropanolamine; Placebos; Quality of Life; Severity of Illness Index; Surveys and Questionnaires; Tolterodine Tartrate; Urinary Bladder, Overactive; Urinary Incontinence, Urge; Young Adult | 2009 |
Combined effects of behavioral intervention and tolterodine in patients dissatisfied with overactive bladder medication.
Topics: Adult; Aged; Aged, 80 and over; Behavior Therapy; Benzhydryl Compounds; Combined Modality Therapy; Cresols; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Patient Satisfaction; Phenylpropanolamine; Tolterodine Tartrate; Urinary Bladder, Overactive; Young Adult | 2009 |
Cost-effectiveness analysis of solifenacin flexible dosing in patients with overactive bladder symptoms in four Nordic countries.
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Cresols; Decision Support Techniques; Female; Finland; Humans; Muscarinic Antagonists; Phenylpropanolamine; Quinuclidines; Randomized Controlled Trials as Topic; Scandinavian and Nordic Countries; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive | 2009 |
Solifenacin in the treatment of overactive bladder syndrome in Italian patients: pharmacoeconomic evaluation.
Topics: Benzhydryl Compounds; Computer Simulation; Cost-Benefit Analysis; Cresols; Humans; Italy; Markov Chains; Muscarinic Antagonists; Pharmacogenetics; Phenylpropanolamine; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive; Urinary Incontinence | 2009 |
Anticholinergic drug use for overactive bladder in Sweden: a nationwide pharmacoepidemiological study.
Topics: Benzhydryl Compounds; Benzofurans; Cholinergic Antagonists; Cresols; Female; Health Care Costs; Humans; Muscarinic Antagonists; Pharmacoepidemiology; Phenylpropanolamine; Pyrrolidines; Quinuclidines; Registries; Retrospective Studies; Solifenacin Succinate; Sweden; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive | 2009 |
Editorial comment.
Topics: Benzhydryl Compounds; Child; Cresols; Drug Therapy, Combination; Humans; Mandelic Acids; Muscarinic Antagonists; Phenylpropanolamine; Tolterodine Tartrate; Urinary Bladder, Overactive | 2009 |
Editorial comment.
Topics: Benzhydryl Compounds; Child; Cresols; Drug Therapy, Combination; Humans; Mandelic Acids; Muscarinic Antagonists; Phenylpropanolamine; Tolterodine Tartrate; Urinary Bladder, Overactive | 2009 |
Editorial comment.
Topics: Benzhydryl Compounds; Child; Cresols; Drug Therapy, Combination; Humans; Mandelic Acids; Muscarinic Antagonists; Phenylpropanolamine; Tolterodine Tartrate; Urinary Bladder, Overactive | 2009 |
Symptomatic and quality of life response to tolterodine in subgroups of men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Age Factors; Aged; Benzhydryl Compounds; Cresols; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Humans; Male; Middle Aged; Muscarinic Antagonists; Patient Satisfaction; Phenylpropanolamine; Probability; Prospective Studies; Prostatic Hyperplasia; Prostatism; Quality of Life; Regression Analysis; Severity of Illness Index; Statistics, Nonparametric; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics | 2010 |
[Clinical efficacy of tolterodine for patients with overactive bladder after insufficient efficacy by monotherapy with alpha1-adrenoceptor antagonist].
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Benzhydryl Compounds; Cresols; Drug Therapy, Combination; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Prostatic Hyperplasia; Quality of Life; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2009 |
Pharmacological and genetic analysis of mechanisms underlying detrusor overactivity in rats.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Afferent Pathways; Animals; Benzhydryl Compounds; Brain; Cerebral Infarction; Cresols; Cyclooxygenase 2; Dinoprostone; Disease Models, Animal; Dose-Response Relationship, Drug; Early Growth Response Protein 1; Excitatory Amino Acid Antagonists; Muscarinic Antagonists; Muscle Contraction; Nerve Fibers, Unmyelinated; Neuronal Plasticity; Phenylpropanolamine; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Receptors, Prostaglandin E; Receptors, Prostaglandin E, EP1 Subtype; RNA, Messenger; Sulfonamides; Tamsulosin; Time Factors; Tolterodine Tartrate; Transcription, Genetic; Urinary Bladder; Urinary Bladder, Overactive | 2010 |
The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
Topics: Benzhydryl Compounds; Benzilates; Cost-Benefit Analysis; Cresols; Decision Trees; Delayed-Action Preparations; Humans; Mandelic Acids; Muscarinic Antagonists; Phenylpropanolamine; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2010 |
Pediatrics: combining antimuscarinics shows promise for overactive bladder.
Topics: Benzhydryl Compounds; Child; Cresols; Drug Therapy, Combination; Humans; Mandelic Acids; Muscarinic Antagonists; Pediatrics; Phenylpropanolamine; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive | 2010 |
Efficacy and safety of tolterodine extended release and dutasteride in male overactive bladder patients with prostates >30 grams.
Topics: Azasteroids; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Dutasteride; Humans; Male; Middle Aged; Muscarinic Antagonists; Organ Size; Phenylpropanolamine; Prostate; Prostatism; Tolterodine Tartrate; Urinary Bladder, Overactive | 2010 |
A prospective observational study of the effects of treatment with extended-release tolterodine on health-related quality of life of patients suffering overactive bladder syndrome in Sweden.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Prospective Studies; Quality of Life; Sweden; Syndrome; Tolterodine Tartrate; Urinary Bladder, Overactive | 2010 |
Fesoterodine fumarate.
Topics: Animals; Benzhydryl Compounds; Clinical Trials as Topic; Cresols; Humans; Muscarinic Antagonists; Phenylpropanolamine; Quality of Life; Tolterodine Tartrate; Urinary Bladder, Overactive | 2010 |
The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Cresols; Humans; Muscarinic Antagonists; Phenylpropanolamine; Tolterodine Tartrate; Urinary Bladder, Overactive | 2010 |
Efficacy of extended-release tolterodine for the treatment of neurogenic detrusor overactivity and/or low-compliance bladder.
Topics: Adult; Aged; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Muscarinic Antagonists; Patient Satisfaction; Phenylpropanolamine; Prospective Studies; Quality of Life; Statistics, Nonparametric; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Neurogenic; Urinary Bladder, Overactive; Urodynamics | 2010 |
Validation of the urinary sensation scale (USS).
Topics: Aged; Benzhydryl Compounds; Cresols; Female; Humans; Linear Models; Male; Multicenter Studies as Topic; Muscarinic Antagonists; Perception; Phenylpropanolamine; Predictive Value of Tests; Randomized Controlled Trials as Topic; Reproducibility of Results; Sensation; Surveys and Questionnaires; Tolterodine Tartrate; Urinary Bladder; Urinary Bladder, Overactive; Urodynamics | 2011 |
Efficacy and tolerability of solifenacin in patients aged ≥ 65 years with overactive bladder: post-hoc analysis of 2 open-label studies.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Clinical Trials as Topic; Cresols; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive | 2011 |
A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; Benzhydryl Compounds; Benzofurans; Blood-Brain Barrier; Brain; Cell Line; Chromatography, High Pressure Liquid; Cresols; Humans; Male; Mandelic Acids; Muscarinic Antagonists; Phenylpropanolamine; Pyrrolidines; Quinuclidines; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Receptors, Muscarinic; Solifenacin Succinate; Tandem Mass Spectrometry; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive | 2011 |
FDA approval signals more 'homework' on the horizon in trials.
Topics: Benzhydryl Compounds; Clinical Trials as Topic; Cresols; Drug Approval; Humans; Muscarinic Antagonists; Phenylpropanolamine; Self Administration; Tolterodine Tartrate; United States; United States Food and Drug Administration; Urinary Bladder, Overactive | 2011 |
Reliability and responsiveness of the Urgency Severity and Life Impact Questionnaire (USIQ).
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cresols; Female; Humans; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Quality of Life; Reproducibility of Results; Severity of Illness Index; Surveys and Questionnaires; Tolterodine Tartrate; Urinary Bladder, Overactive | 2012 |
Re: Symptomatic and quality of life response to tolterodine in subgroups of men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia.
Topics: Benzhydryl Compounds; Cresols; Humans; Male; Muscarinic Antagonists; Phenylpropanolamine; Prostatic Hyperplasia; Prostatism; Quality of Life; Urinary Bladder, Overactive | 2011 |
Cost-effectiveness of percutaneous tibial nerve stimulation versus extended release tolterodine for overactive bladder.
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Cresols; Decision Trees; Delayed-Action Preparations; Female; Humans; Muscarinic Antagonists; Phenylpropanolamine; Tibial Nerve; Tolterodine Tartrate; Transcutaneous Electric Nerve Stimulation; Urinary Bladder, Overactive | 2012 |
Silicone adhesive, a better matrix for tolterodine patches-a research based on in vitro/in vivo studies.
Topics: Adhesives; Administration, Cutaneous; Animals; Benzhydryl Compounds; Biological Availability; Chemistry, Pharmaceutical; Cresols; Drug Delivery Systems; Male; Myristates; Phenylpropanolamine; Rabbits; Silicones; Skin; Skin Absorption; Tolterodine Tartrate; Transdermal Patch; Urinary Bladder, Overactive | 2012 |
Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Benzhydryl Compounds; Cresols; Dose-Response Relationship, Drug; Female; Infusions, Intravenous; Muscarinic Antagonists; Phenylpropanolamine; Rats; Rats, Sprague-Dawley; Thiazoles; Tolterodine Tartrate; Urinary Bladder Neck Obstruction; Urinary Bladder, Overactive; Urination | 2012 |
Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective study.
Topics: Aged; Aging; Benzhydryl Compounds; Cohort Studies; Cresols; Cross-Sectional Studies; Delayed-Action Preparations; Drug Substitution; Female; Humans; Male; Middle Aged; Phenylpropanolamine; Retrospective Studies; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2012 |
Combination of baclofen and antimuscarinics to reduce voiding difficulty in treating women with overactive bladders.
Topics: Adult; Aged; Baclofen; Benzhydryl Compounds; Community-Based Participatory Research; Cresols; Drug Therapy, Combination; Female; Humans; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Tolterodine Tartrate; Urinary Bladder, Overactive; Urination; Urodynamics; Young Adult | 2012 |
Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Benzhydryl Compounds; Cresols; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Quality of Life; Randomized Controlled Trials as Topic; Surveys and Questionnaires; Time Factors; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive; Urinary Incontinence, Urge; Urination; Young Adult | 2012 |
Re: Cost-effectiveness of percutaneous tibial nerve stimulation versus extended release tolterodine for overactive bladder: H. W. Chen, R. S. Bercik, E. F. Werner And S. F. Thung; J Urol 2012; 187: 178-184.
Topics: Benzhydryl Compounds; Cresols; Female; Humans; Muscarinic Antagonists; Phenylpropanolamine; Transcutaneous Electric Nerve Stimulation; Urinary Bladder, Overactive | 2012 |
Mirabegron as a new class of oral drug for overactive bladder syndrome: many positive perspectives, some concerns.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Benzhydryl Compounds; Cresols; Female; Humans; Male; Muscarinic Antagonists; Phenylpropanolamine; Thiazoles; Tolterodine Tartrate; Urinary Bladder, Overactive | 2013 |
[Comment on the STAR study: Comparison of the efficacy and tolerance of solifenacin and tolterodine retard in the treatment of overactive bladder].
Topics: Analysis of Variance; Benzhydryl Compounds; Controlled Clinical Trials as Topic; Cresols; Double-Blind Method; Drug Tolerance; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Prospective Studies; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence | 2006 |
Re: safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.
Topics: Benzhydryl Compounds; Cresols; Humans; Male; Muscarinic Antagonists; Phenylpropanolamine; Tolterodine Tartrate; Urinary Bladder Neck Obstruction; Urinary Bladder, Overactive | 2006 |
Retrospective evaluation of outcomes in patients with overactive bladder receiving tolterodine versus oxybutynin.
Topics: Benzhydryl Compounds; Comorbidity; Cresols; Delayed-Action Preparations; Depression; Female; Fractures, Bone; Humans; Male; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Retrospective Studies; Risk; Tolterodine Tartrate; United States; Urinary Bladder, Overactive; Urinary Tract Infections | 2006 |
[More quality of life again with tolterodine].
Topics: Benzhydryl Compounds; Cresols; Humans; Muscarinic Antagonists; Phenylpropanolamine; Quality of Life; Tolterodine Tartrate; Urinary Bladder, Overactive | 2006 |
Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents.
Topics: Animals; Atropine; Benzhydryl Compounds; Benzilates; Benzofurans; Binding, Competitive; Carbachol; CHO Cells; Cholinergic Agonists; Cresols; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; In Vitro Techniques; Male; Mandelic Acids; Muscarinic Antagonists; Muscle Contraction; Muscle, Smooth; N-Methylscopolamine; Phenylpropanolamine; Pyrrolidines; Quinuclidines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Muscarinic; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Transfection; Urinary Bladder; Urinary Bladder, Overactive; Urination | 2007 |
Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder.
Topics: Animals; Benzhydryl Compounds; Benzofurans; Cerebral Cortex; Cresols; In Vitro Techniques; Male; Mandelic Acids; Mice; Muscarinic Antagonists; Phenylpropanolamine; Pyrrolidines; Receptors, Muscarinic; Tolterodine Tartrate; Urinary Bladder; Urinary Bladder, Overactive | 2007 |
[Urinary symptoms and urodynamic findings in Parkinson's disease].
Topics: Aged; Benzhydryl Compounds; Cresols; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Parkinson Disease; Phenylpropanolamine; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urodynamics | 2007 |
Treatment of men with lower urinary tract symptoms and overactive bladder.
Topics: Adrenergic alpha-Antagonists; Aged; Benzhydryl Compounds; Cost-Benefit Analysis; Cresols; Drug Therapy, Combination; Humans; Male; Muscarinic Antagonists; Patient Satisfaction; Phenylpropanolamine; Prostatic Hyperplasia; Sulfonamides; Tamsulosin; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence, Urge | 2007 |
Treatment of men with lower urinary tract symptoms and overactive bladder.
Topics: Adrenergic Agonists; Adrenergic alpha-Antagonists; Aged; Benzhydryl Compounds; Cresols; Drug Interactions; Drug Therapy, Combination; Histamine H1 Antagonists; Humans; Male; Muscarinic Antagonists; Phenylpropanolamine; Prostatic Hyperplasia; Sulfonamides; Tamsulosin; Tolterodine Tartrate; Urinary Bladder, Overactive; Urinary Incontinence, Urge | 2007 |
[Comment on the STAR study: Comparison of the efficacy and tolerance of solifenacin and tolterodine retard in the treatment of overactive bladder].
Topics: Analysis of Variance; Benzhydryl Compounds; Cresols; Double-Blind Method; Drug Tolerance; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Prospective Studies; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive | 2007 |
Long-term efficacy of tolterodine and patient compliance in pediatric patients with neurogenic detrusor overactivity.
Topics: Benzhydryl Compounds; Child; Cresols; Female; Follow-Up Studies; Humans; Male; Muscarinic Antagonists; Patient Compliance; Phenylpropanolamine; Time Factors; Tolterodine Tartrate; Urinary Bladder, Neurogenic; Urinary Bladder, Overactive | 2007 |
Cognitive dysfunction with tolterodine use.
Topics: Aged; Benzhydryl Compounds; Cognition Disorders; Cresols; Female; Humans; Phenylpropanolamine; Tolterodine Tartrate; Urinary Bladder, Overactive | 2007 |
Efficacy of tolterodine in women with detrusor overactivity and anterior vaginal wall prolapse: is it the same?
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Female; Humans; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Prospective Studies; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Uterine Prolapse | 2007 |
Effects of antimuscarinics on voiding function after cerebral infarction in a rat model of overactive bladder.
Topics: Animals; Atropine; Benzhydryl Compounds; Cresols; Dose-Response Relationship, Drug; Female; Infarction, Middle Cerebral Artery; Injections, Intraventricular; Muscarinic Antagonists; Muscle Contraction; Muscle, Smooth; Phenylpropanolamine; Rats; Rats, Sprague-Dawley; Tolterodine Tartrate; Urinary Bladder; Urinary Bladder, Overactive; Urinary Catheterization; Urination | 2007 |
Editorial comment on: Urinary incontinence at orgasm: relation to detrusor overactivity and treatment efficacy.
Topics: Benzhydryl Compounds; Cresols; Female; Humans; Muscarinic Antagonists; Orgasm; Phenylpropanolamine; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence | 2008 |
Editorial comment on: Urinary incontinence at orgasm: relation to detrusor overactivity and treatment efficacy.
Topics: Benzhydryl Compounds; Cresols; Female; Humans; Muscarinic Antagonists; Orgasm; Phenylpropanolamine; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence | 2008 |
Urinary incontinence at orgasm: relation to detrusor overactivity and treatment efficacy.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cresols; Female; Humans; Middle Aged; Muscarinic Antagonists; Orgasm; Phenylpropanolamine; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Young Adult | 2008 |
Thorough QT study with recommended and supratherapeutic doses of tolterodine.
Topics: Benzhydryl Compounds; Cresols; Dose-Response Relationship, Drug; Drug Labeling; Humans; Long QT Syndrome; Muscarinic Antagonists; Patient Selection; Phenylpropanolamine; Research Design; Risk Assessment; Risk Factors; Tolterodine Tartrate; Urinary Bladder, Overactive | 2008 |
Efficacy of tolterodine in relation to different urodynamic findings of detrusor overactivity.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Body Mass Index; Cresols; Female; Follow-Up Studies; Humans; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Prospective Studies; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics | 2008 |
The effects of a type 4 phosphodiesterase inhibitor and the muscarinic cholinergic antagonist tolterodine tartrate on detrusor overactivity in female rats with bladder outlet obstruction.
Topics: Animals; Benzhydryl Compounds; Cresols; Female; Muscarinic Antagonists; Muscle, Smooth; Phenylpropanolamine; Phosphodiesterase Inhibitors; Rats; Rats, Sprague-Dawley; Tolterodine Tartrate; Urinary Bladder; Urinary Bladder Neck Obstruction; Urinary Bladder, Overactive; Urodynamics | 2008 |
In vivo characterization of muscarinic receptors in peripheral tissues: evaluation of bladder selectivity of anticholinergic agents to treat overactive bladder.
Topics: Administration, Oral; Animals; Area Under Curve; Benzhydryl Compounds; Benzilates; Cholinergic Antagonists; Cresols; Male; Mandelic Acids; Mice; Muscarinic Antagonists; Phenylpropanolamine; Protein Binding; Quinuclidinyl Benzilate; Receptors, Muscarinic; Time Factors; Tolterodine Tartrate; Urinary Bladder, Overactive | 2008 |
Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan.
Topics: Adult; Aged; Benzhydryl Compounds; Cohort Studies; Cresols; Databases, Factual; Delayed-Action Preparations; Female; Follow-Up Studies; Humans; Male; Managed Care Programs; Mandelic Acids; Middle Aged; Multivariate Analysis; Muscarinic Antagonists; Patient Compliance; Phenylpropanolamine; Retrospective Studies; Tolterodine Tartrate; Treatment Refusal; United States; Urinary Bladder, Overactive | 2008 |
Human urine with solifenacin intake but not tolterodine or darifenacin intake blocks detrusor overactivity.
Topics: Administration, Oral; Animals; Benzhydryl Compounds; Benzofurans; Cresols; Disease Models, Animal; Female; Humans; Muscarinic Antagonists; Muscle, Smooth; Phenylpropanolamine; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Muscarinic M3; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urine | 2008 |